Xtandi Smashes Primary Goal in Patients with mHSPC in PIII Trial

The prostate cancer treatment Xtandi (enzalutamide) met its primary endpoint in a PIII clinical trial significantly extending radiographic progression-free survival (rPFS) in men with metastatic hormone-sensitive prostate cancer (mHSPC), Astellas Pharma and Pfizer said on December 20. The trial, called...read more